Recently, Leadingpharm won the title of Beijing Intellectual Property Advantage Unit in 2023 due to its outstanding ability of innovation and intellectual property management. This honor is a full recognition of Leadingpharm in terms of intellectual property creation, protection, and application, and also a great encouragement for the company's continuous innovation and core competitiveness enhancement.
 

The evaluation of Beijing Intellectual Property Advantage Unit was carried out by the Beijing Intellectual Property Bureau. In accordance with the Beijing Intellectual Property Pilot Demonstration Unit Identification and Management Measures, the evaluation conducts multiple stages such as initial review, formal review, expert evaluation, and public announcement, comprehensively evaluating the quantity of intellectual property, technological research and development strength, research and development funding investment, intellectual property application and protection, and other aspects. Enterprises selected as Beijing Intellectual Property Advantage Unit need to possess intellectual property strategic planning and management concepts, as well as a sound intellectual property management system, and comprehensively develop in the creation, application, protection, and management of intellectual property. They are benchmark demonstration enterprises with outstanding comprehensive competitive advantages and industry influence. The selection of Leadingpharm  as a unit of intellectual property advantage in Beijing is a high recognition and affirmation of Leadingpharm's intellectual property management system, technological research and development capabilities, scientific research achievements, and other intellectual property series work.
 

As a leading pharmaceutical enterprise in China, Leadingpharm has always been committed to promoting the development of China's pharmaceutical industry through innovative research and development, service models, and information technology. Focusing on the research and development of high-tech barrier drugs and the transformation of innovative drug research, continuously increasing investment in independent research and development, enriching clinical drug choices, and improving the quality of clinical drug use; At the same time, leveraging the advantages of Leadingpharm's CXO Whole Industry Chain System, strengthening industry-university-research cooperation, actively promoting the transformation of innovative achievements in universities, and playing an important role in accelerating the construction of high-precision and cutting-edge economic structures of Beijing and China.
 

In addition, Leadingpharm has always attached great importance to the creation, protection, and application of intellectual property rights. Leadingpharm has a high-quality intellectual property management team, established a sound intellectual property management system, actively carried out intellectual property training and cultural construction, and continuously improved its intellectual property creation ability and protection level. In recent years, Leadingpharm has participated in the formulation of more than 10 national and industry standards, published more than 20 journal articles, applied for nearly 100 patents, and published more than 130 original technical articles. The title of Intellectual Property Advantage Unit is another important achievement in the field of intellectual property for Leadingpharm since it was awarded the title of Intellectual Property Pilot Unit of Beijing in 2020. Not only does it demonstrate the company's strength and advantages in the field of intellectual property, but it also injects strong impetus into the company's sustainable development.
 

Looking ahead to the future, Leadingpharm will continue to increase investment in research and development innovation and intellectual property protection, continuously improve its intellectual property management system, enhance the efficiency of intellectual property application, and strive to build the company into a benchmark enterprise for intellectual property in the pharmaceutical industry. At the same time, Leadingpharm will actively leverage its own advantages, promote intellectual property cooperation and exchange within the industry, and contribute to enhancing the innovation capability and core competitiveness of the entire pharmaceutical industry.